Therapies we are testing:
A new, unlicensed drug called Namilumab that has been tested in patients with rheumatoid arthritis and other inflammatory conditions. It may reduce the numbers of highly activated inflammatory macrophages in the lungs and thereby dampen the inflammation in the body caused by the coronavirus. Our Namilumab Arm has closed and we are no longer recruiting patients to Namilumab.
A drug called Infliximab (Remsima), which is widely used to treat rheumatoid arthritis and other inflammatory conditions such as Crohn’s Disease. It blocks the action of a critical cytokine, known as TNF, which is produced by activated macrophages and drives inflammation. In doing this, Infliximab may reduce inflammation in the body caused by the coronavirus. Our Infliximab Arm has closed and we are no longer recruiting patients to Infliximab.
By reducing the excessive inflammation that occurs in patients with more severe COVID-19, it is thought the immune system will adapt to fight off the virus more effectively.